Gain Therapeutics (GANX)
Develops allosteric medicines and rexaceract for Parkinson’s disease.
$1.87
vs last close−0.08 (−4.36%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 19.84% | 8.66M shares | |
|---|---|---|---|
| 54 holders · as of Jun 30, 2026 | |||
| Other | 80.16% | 34.98M shares | |
| remainder | |||
43.64M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
54 holders · 8.66M shares · 12 new positions · 26 increased · 9 reduced · 4 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Marshall Wace, LLP | 1.92M | 4.41% | +153.8K | Aug 13, 2026 |
| Potomac Capital Management, Inc. | 946.4K | 2.17% | −62.2K | Aug 14, 2026 |
| Gsa Capital Partners LLP | 632.1K | 1.45% | +319.7K | Aug 6, 2026 |
| Jones Financial Companies LLLP | 608.6K | 1.39% | −23.0K | Aug 14, 2026 |
| Cambridge Investment Research Advisors, Inc. | 568.6K | 1.30% | 0 | Jul 30, 2026 |
| Dme Capital Management, LP | 566.1K | 1.30% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 480.3K | 1.10% | +80.4K | Aug 13, 2026 |
| Geode Capital Management, LLC | 453.5K | 1.04% | +6.2K | Aug 12, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.